RESUMO
Because of the frequent treatment of dairy cows with nitroxynil (NTX), the presence of the later residues in animal tissues and milk has a significant concern. The quantum yield of the reaction product was calculated. A highly sensitive and rapid spectrofluorometric method for determining the anthelmintic drug (NTX) residual amounts is developed. The proposed approach is based on using Zn/HCl to reduce NTX nitro group to an amino group, resulting in a highly fluorescent derivative that was detected at each of λem 302â¯nm and 364â¯nm after excitation at λexâ¯=â¯277â¯nm. The experimental conditions were carefully studied and optimized. The proposed approach showed good linearity (r2â¯≥â¯0.9998) with linearity range of 10.0-100.0â¯ng/mL with a detection limit of 1.89â¯ng/mL, 1.27â¯ng/mL and quantification limit of 5.73â¯ng/mL, 3.86â¯ng/mL at λem 302â¯nm and 364â¯nm, respectively; that is far below the Minimum Regulatory Limits (MRLs) of NTX in animal tissues and milk. The proposed approach was successfully applied for the analysis of the drug in its veterinary formulations, and the obtained results agreed well with those of the official British Pharmacopeia method. Moreover, the proposed method's application was extended to efficiently determine the residues of nitroxynil in meat, liver, kidney and milk samples.
Assuntos
Anti-Helmínticos , Nitroxinila , Animais , Bovinos , Feminino , Leite/química , Nitroxinila/análise , Espectrometria de Fluorescência/métodosRESUMO
Antineoplastic drugs, etoposide (ETO), are widely used in leukaemia. A patient with leukaemia has a relative infection with pneumonia treated by fluoroquinolones as moxifloxacin HCL (MOX). Because opioid analgesic as nalbuphine HCL (NAL) does not have a ceiling dose, it is used to manage the distasteful sensory in leukaemia. Consequently, green methods for synchronous spectrofluorimetric quantification of a ternary mixture of ETO, MOX and NAL were developed. The first approach relies simply on the estimation of MOX at 371 nm by conventional synchronous fluorimetric technique (Δλ of 60 nm). The second approach depends on applying the first derivative synchronous fluorimetric technique (Δλ of 60 nm) for simultaneous estimation of ETO and NAL at 257 and 273 nm, respectively. A good linear correlation was obtained in the ranges of 0.04-0.40, 0.10-1.00 and 0.50-5.00 µg ml-1 for MOX, ETO and NAL, respectively. Moreover, the proposed approaches were successfully applied for the estimation of the studied drugs in the pharmaceutical dosage forms. Additionally, the synchronous assessment of ETO, MOX and NAL in the spiked human urine was successfully attained by the facile protein precipitation technique. The mean % recoveries in spiked human urine were 99.49, 98.07 and 98.48 for MOX, ETO and NAL, respectively.
RESUMO
The growth of tumor tissue is extremely pervasive among post-menopausal women. Commonly, from the clinical application, adjuvant selective estrogen receptor modulators such as tamoxifen are prescribed for prohibiting metastatic breast cancer, while its analog, clomiphene, is used to treat infertility in women. Lately, the significance of green chemistry on our environment was through reducing the influence of hazardous chemicals. Consequently, efforts were screened to perform a fast and simple eco-friendly green method for the determination of two aromatase inhibitors. In this study, a sensitive green spectrofluorimetric approach was developed to detect and characterize tamoxifen citrate (TAM) and clomiphene citrate (CLO) via complex formation with erythrosine B. The reaction between erythrosine B dye (EB) and the two aromatase inhibitors results in quenching the fluorescence activity of the dye by the formation of ion-pair in Britton-Robinson buffer (BRB) solution (pH 4.3) at 554 nm (λex = 527 nm). The approach outcome confirmed that the solvent's inherent nature has a critical impact on the approachs' sensitivity and reproducibility. An approved linear correlation was achieved between the reduction in the emission value of EB's fluorescence and the concentration in the ranges of 40.0-600.0 ng/mL for both TAM and CLO with mean % recoveries 100.20 ± 0.93 and 100.07 ± 1.09, respectively. The approach was validated regarding ICH protocols, and the outcomes were acceptable. The changes in Gibb's free energy (ΔG°) by the obtained ion-pair between EB and TAM or CLO were -36.65 or -37.03 kJ mol-1, respectively, which indicates the reaction feasibility at ambient temperature. Commercial dosage forms for TAM and CLO were simply analyzed, and good recoveries were achieved within the range. The National Environmental Methods Index, Analytical Eco-Scale, and Green Analytical Procedure Index applications to our illustrated approach present additional eligibility to this study.
Assuntos
Clomifeno , Eritrosina , Feminino , Corantes Fluorescentes , Humanos , Reprodutibilidade dos Testes , TamoxifenoRESUMO
In the present study, we conducted two facile and highly sensitive spectrofluorimetric approaches in order to quantify the vasoprotective agents; troxerutin (TROX) and calcium dobesilate (DOB) in the presence of hydroquinone (HQ) (as a highly toxic impurity and potential degradation product of DOB) in commercial formulations and human plasma. The first approach relies simply on using ethanol as an eco-friendly solvent for the estimation of DOB at 345 nm after being excited at 305 nm. The linearity was carefully investigated between DOB concentration and the relative fluorescence intensity in the range of 0.05-0.8 µg ml-1. Due to the high method simplicity and sensitivity, applying the first approach to quality control analysis and spiked human plasma samples with mean % recoveries 100.74 ± 3.71 adds another merit. The second approach involved rapid conventional fluorimetric estimation of ethanolic TROX solution in TROX/DOB combined dosage forms at 455/350 nm (emission/excitation) with a linear calibration chart covering the range of 0.1-1.2 µg ml-1. Moreover, the second approach involved a comprehensive study in a trial to solve the problem of superposition of DOB and HQ graph adopting the first derivative synchronous fluorimetric mechanism in ethanol at Δλ = 60 nm. Therefore, DOB was measured at 286 and 323 nm, while HQ could be quantitated at 301 nm. The Beer-Lambert Law has complied over the ranges of 0.1-1.0 and 0.02-0.4 µg ml-1 for DOB and HQ, respectively. Guidelines adopted by the International Council of Harmonization (ICH) were used to validate the target approaches. The developed methods are more convenient for routine quality control laboratory instead of the time-consuming and sophisticated reported techniques. Moreover, different aspects of evaluating the greenness of the proposed approaches were conducted to have a complete image of their environmental impact.
RESUMO
In the present study, different spectroscopic techniques have been used to study the binding interaction between the antidepressant drug fluvoxamine and human serum albumin under simulated physiological conditions (pH 7.4). The utilized spectroscopic techniques include fluorescence emission spectroscopy, synchronous fluorescence spectroscopy, UV-Vis absorption spectroscopy, Fourier Transform Infrared spectroscopy (FT-IR), and molecular modeling methods. The obtained results revealed that the formation of a complex between human serum albumin and fluvoxamine was responsible for quenching the native fluorescence of human serum albumin. The results indicated that the quenching mechanism between human serum albumin and fluvoxamine was static. Besides, the binding constant (K), number of binding sites (n), thermodynamic parameters (ΔH, ΔS, and ΔG), and binding forces were calculated at three different temperatures (298, 310, and 318 K). These data proposed that hydrophobic forces were the principal intermolecular forces stabilizing the complex. From the molecular docking results, it could be deduced that fluvoxamine was inserted into sub-domain II A (site I) of human serum albumin and led to a slight change in human serum albumin conformation.
Assuntos
Fluvoxamina , Simulação de Acoplamento Molecular , Albumina Sérica Humana , Sítios de Ligação , Dicroísmo Circular , Humanos , Ligação Proteica , Soroalbumina Bovina/metabolismo , Espectrometria de Fluorescência , Espectroscopia de Infravermelho com Transformada de Fourier , TermodinâmicaRESUMO
Cisatracurium besylate has been determined by fast and highly sensitive spectrofluorimetric method based on measuring the fluorescence intensity of its methanolic solution at 312 nm after excitation at 230 nm (Method I). The linearity occurred over the concentration range of 10.0-130.0 ng/mL with detection limit of 1.07 ng/mL. The method was further extended for the determination of the studied drug in spiked human plasma with good percentage recoveries (97.43-103.50%). Cisatracurium is co-administered with nalbuphine during surgery. The simultaneous determination of both drugs was based on synchronous spectrofluorimetric technique. First derivative synchronous spectrofluorimetric amplitude was measured in methanol at Δ λ = 60 nm and each drug could be estimated at the zero crossing point of the other. Hence, cisatracurium could be measured at 284.6 nm while nalbuphine at 276.3 nm (Method II). The method was linear over the ranges of 50.0-750.0 ng/mL and 0.5-7.0 µg/mL with the detection limits of 2.16 ng/mL and 0.04 µg/mL for cisatracurium and nalbuphine, respectively. The method was further extended for the simultaneous determination of both drugs in spiked human urine with mean percentage recoveries of 99.99 ± 2.06 and 99.53 ± 6.17 for cisatracurium and nalbuphine, respectively. Both methods were validated in agreement with Guidelines adopted by International Council of Harmonization (ICH).
Assuntos
Atracúrio/análogos & derivados , Nalbufina/sangue , Nalbufina/urina , Espectrometria de Fluorescência/métodos , Urinálise/métodos , Atracúrio/sangue , Atracúrio/urina , Calibragem , Formas de Dosagem , Humanos , Limite de Detecção , Reprodutibilidade dos Testes , SolventesRESUMO
Propofol and cisatracurium besylate have been simultaneously determined using a highly sensitive first derivative synchronous spectrofluorometric method. The method is based on measuring first derivative synchronous spectrofluorimetric amplitude at Δλ = 40 nm with a scanning rate of 600 nm/min. The different experimental parameters affecting the fluorescence intensity of the two drugs were carefully studied and optimized. The amplitude-concentration plots were rectilinear over the range 40.0-400.0 ng/mL and 20.0-280.0 ng/mL for propofol and cisatracurium, respectively with lower detection limits of 4.0 and 2.35 ng/mL and quantification limits of 12.1 and 7.1 ng/mL for propofol and cisatracurium, respectively. The proposed method was successfully applied for the determination of the two compounds in synthetic mixtures and in commercial ampoules. The high sensitivity attained using the proposed method allowed the simultaneous determination of both drugs in spiked plasma samples. The mean % recoveries in spiked human plasma (n = 3) were 96.53 ± 0.90 and 96.20 ± 1.64 for each of propofol and cisatracurium, respectively. The method was validated in compliance with International Council of Harmonization (ICH) Guidelines.
Assuntos
Atracúrio/análogos & derivados , Propofol/sangue , Espectrometria de Fluorescência , Atracúrio/sangue , Atracúrio/química , Humanos , Estrutura Molecular , Propofol/químicaRESUMO
A novel, quick, simple and highly sensitive spectrofluorimetric method was developed and validated for the determination of sitagliptin (SG) in its pharmaceutical formulations. The proposed method is based on investigation of the fluorescence spectral behavior of sitagliptin in an SDS micellar system. In an aqueous solution of phosphate buffer pH 4.0, the fluorescence intensity of SG in the presence of SDS was greatly enhanced, by 200%, i.e. twofold enhancement. The fluorescence intensity of SG was measured at 300 nm after excitation at 270 nm. The method showed good linearity in the range 0.03-10.0 µg/mL with a good correlation coefficient (r = 0.9998). The limits of detection and quantitation values were 5.31 and 16.1 ng/mL, respectively. The proposed method was successfully applied to the analysis of SG in its single and co-formulated commercial tablets; the results were in good agreement with those obtained using a reference method. Application of the proposed method was extended to stability studies of SG after exposure to different forced degradation conditions according to the ICH guidelines, such as acidic, alkaline, thermal, photo- and oxidative stress. The chemical structure of certain potential degradation products (DPs) were investigated using LC-MS.
Assuntos
Álcalis/química , Cromatografia Líquida/métodos , Hipoglicemiantes/análise , Espectrometria de Massas/métodos , Micelas , Pirazinas/análise , Espectrometria de Fluorescência/métodos , Triazóis/análise , Limite de Detecção , Fosfato de SitagliptinaRESUMO
A simple and sensitive spectrofluorimetric method was developed for the determination of biotin in pure form and in pharmaceutical preparations. The proposed method is based on the oxidation of the drug with cerium (IV) ammonium sulfate in acidic medium. The fluorescence of the produced Cerium (III) was measured at 365 nm after excitation at 255 nm. The different experimental parameters affecting the development and stability of the reaction were carefully studied and optimized. The method is applicable over the concentration range of 30-120 ng/mL with correlation coefficient of 0.9998. The detection limit (LOD) of biotin was 2.41 ng/mL while quantitation limit (LOQ) was 7.29 ng/mL. The proposed procedure was successfully applied for the determination of biotin in pharmaceutical preparations with mean recoveries of 99.55 ± 0.83 and 101.67 ± 1.53 for biotin ampoules and capsules, respectively. The results obtained were in good agreement with those obtained using the official method.
RESUMO
A simple accurate kinetic spectrophotometric method was developed for the determination of biotin in pure form and pharmaceutical preparations. The proposed method is based on a catalytic acceleration of biotin on the reaction between sodium azide and tri-iodide in an aqueous solution. Concentration range of 4-16 µg/mL for biotin was determined by measuring the decrease in the absorbance of tri-iodide at 348 nm by a fixed time method. The decrease in absorbance after 14 min from the initiation of the reaction was markedly correlated to the concentration with correlation coefficient of 0.9999. The detection limit (LOD) of biotin was 0.18 µg/mL while quantitation limit (LOQ) was 0.54 µg/mL. The percentage recovery of the spiked samples was 100.08 ± 0.761. The proposed procedure was successfully applied for the determination of biotin in its pharmaceutical preparations with mean recoveries of 101.17 ± 2.05 and 97.87 ± 1.50 for biotin ampoules and capsules, respectively. The results obtained were in good agreement with those obtained using official method.
RESUMO
The mts1 gene codes for a 101 amino acid protein belonging to the S100 subfamily of Ca(2+)-binding proteins. Mts1 is overexpressed in metastatic cancers as compared to their nonmetastatic counterparts, and although mts1 is known to be involved in the metastatic phenotype (Davies et al., 1993; Grigorian et al., 1993), the role mts1 plays in this process is not clearly understood. In order to determine what role mts1 plays in the process of metastasis, we have performed transfection studies on nonmetastatic and metastatic mouse mammary adenocarcinoma cell lines, CSML0 and CSML100, respectively (Senin et al., 1983, 1984). The metastatic variant, CSML100, expresses high levels of mts1, whereas the nonmetastatic variant, CSML0, expresses almost no mts1. CSML0 cells transfected with mts1 were assessed in in vitro motility and invasion assays, as well as in vivo metastasis assays to determine the role of mts1 in these processes. Cell lines expressing mts1 display an altered morphology as well as increased motility in modified Boyden chemotaxis chambers. However, no significant increase in in vitro invasion or in in vivo metastasis was observed. Therefore, the presence of mts1 may be important for metastasis by increasing motility, but may not be sufficient for invasion in vitro or metastasis in vivo. Very low levels of type IV collagenase activities were observed in CSML0 cells and the transfectants, as opposed to the highly metastatic CSML100 cells, where high levels of type IV collagenase activities were observed. It is possible that the presence of these proteases in addition to mts1 may be responsible for the high metastatic potential of the CSML100 in vivo.